Literature DB >> 15549420

[Cannabinoids--signal transduction and mode of action].

R Rukwied1, B Gauter, M Schley, C Konrad.   

Abstract

The therapeutic use of cannabinoids, the components of cannabis sativa L., was investigated in numerous researches in detail. Animal studies revealed that cannabinoid receptor agonists alter pain-associated behaviour, have immune-suppressive properties, suppress tumor growth, modulate sensitisation processes and influence memory and learning. Those effects are mediated by two membrane-bound cannabinoid receptors and as mechanisms of signal transduction blockade of ion channels, inhibition of adenylate cyclase and retrograde inhibition of neurotransmitter release are currently being discussed. In clinical studies oral administration of cannabinoids indicated beneficial results during the therapy of multiple sclerosis, weight loss, nausea and vomiting due to chemotherapy, and intractable pruritus. However, therapy of chronic pain conditions revealed conflicting results and unequivocal success could not have been delivered due to unwanted side effects. Further multicentre studies are required to estimate cannabinoids as novel therapeutic tools for the treatment of chronic pain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15549420     DOI: 10.1007/s00482-004-0349-8

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  180 in total

Review 1.  Endogenous cannabinoid signaling.

Authors:  D Piomelli; M Beltramo; A Giuffrida; N Stella
Journal:  Neurobiol Dis       Date:  1998-12       Impact factor: 5.996

2.  Cannabinoid agonists attenuate capsaicin-induced responses in human skin.

Authors:  Roman Rukwied; Allan Watkinson; Francis McGlone; Melita Dvorak
Journal:  Pain       Date:  2003-04       Impact factor: 6.961

3.  Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site.

Authors:  M Barann; G Molderings; M Brüss; H Bönisch; B W Urban; M Göthert
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

4.  Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons.

Authors:  N Auclair; S Otani; P Soubrie; F Crepel
Journal:  J Neurophysiol       Date:  2000-06       Impact factor: 2.714

5.  Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration.

Authors:  Diana L Cichewicz; Erin A McCarthy
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

6.  The endogenous cannabinoid system protects against colonic inflammation.

Authors:  Federico Massa; Giovanni Marsicano; Heike Hermann; Astrid Cannich; Krisztina Monory; Benjamin F Cravatt; Gian-Luca Ferri; Andrei Sibaev; Martin Storr; Beat Lutz
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 7.  Role of endogenous cannabinoids in synaptic signaling.

Authors:  Tamas F Freund; Istvan Katona; Daniele Piomelli
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

8.  Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat.

Authors:  Zsuzsanna Helyes; József Németh; Márta Thán; Kata Bölcskei; Erika Pintér; János Szolcsányi
Journal:  Life Sci       Date:  2003-09-19       Impact factor: 5.037

9.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

10.  Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.

Authors:  Guy W Neff; Christopher B O'Brien; K Rajender Reddy; Nora V Bergasa; Arie Regev; Enrique Molina; Rafael Amaro; Miguel J Rodriguez; VeEtta Chase; Lennox Jeffers; Eugene Schiff
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

View more
  4 in total

1.  Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey.

Authors:  Janet Weber; Marcus Schley; Matthias Casutt; Helmut Gerber; Guido Schuepfer; Roman Rukwied; Wolfgang Schleinzer; Michael Ueberall; Christoph Konrad
Journal:  Anesthesiol Res Pract       Date:  2009-10-25

2.  [Respiratory failure due to delta-9-tetrahydrocannabinol in a tetraplegic patient].

Authors:  M Neuburger; M Schley; M Schmelz; G Schuepfer; C Konrad
Journal:  Schmerz       Date:  2006-11       Impact factor: 1.107

3.  [History of pain therapy. Pain in a medical, historical and social context].

Authors:  R Sabatowski; M Zimmermann
Journal:  Schmerz       Date:  2007-08       Impact factor: 1.629

4.  Uremic Pruritus Is Not Associated with Endocannabinoid Receptor 1 Gene Polymorphisms.

Authors:  Monika Heisig; Łukasz Łaczmański; Adam Reich; Felicja Lwow; Jacek C Szepietowski
Journal:  Biomed Res Int       Date:  2016-02-29       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.